Please use this identifier to cite or link to this item: https://hdl.handle.net/11147/9488
Title: KRAS(G12C) inhibitors on the horizon
Authors: Çağır, Ali
Azmi, Asfar S.
Keywords: Inhibitors
KRAS
KRAS(G12C)
KRAS(G12D)
RAS
Therapy resistance
Issue Date: 2019
Publisher: Future Science
Abstract: RAS proteins (the four isoforms KRAS4A, KRAS4B, NRAS and HRAS encoded by three genes KRAS, NRAS and HRAS) act as molecular switches that when activated drive several key cellular processes such as cell growth, proliferation and survival [1]. In normal cells, RAS activity is under tight control by the precise activation (binding to GTP) and inactivation (GTP hydrolysis to GDP) [1]. As with other critical proteins, it is not at all surprising to note that the gene encoding the RAS protein isoforms is found mutated or altered in a significant proportion of tumors [2]. Mutant RAS loses its ability to hydrolyze GTP and remains in a permanently activated state (bound to GTP) leading to uncontrolled growth.
URI: https://doi.org/10.4155/fmc-2018-0304
https://hdl.handle.net/11147/9488
ISSN: 1756-8919
1756-8927
Appears in Collections:Chemistry / Kimya
PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File SizeFormat 
fmc-2018-0304.pdf165.38 kBAdobe PDFView/Open
Show full item record



CORE Recommender

SCOPUSTM   
Citations

7
checked on Dec 9, 2023

WEB OF SCIENCETM
Citations

5
checked on Jun 19, 2023

Page view(s)

16
checked on Dec 4, 2023

Download(s)

4
checked on Dec 4, 2023

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.